NYSTATIN Drug Patent Profile
✉ Email this page to a colleague
When do Nystatin patents expire, and when can generic versions of Nystatin launch?
Nystatin is a drug marketed by Actavis Mid Atlantic, Cosette, Crown Labs Inc, Fougera Pharms, Macleods Pharms Ltd, Padagis Us, Strides Pharma, Taro, Torrent, Lyne, Zydus Lifesciences, Paddock Llc, Adrastea Pharma, Dr Reddys Labs Sa, Epic Pharma Llc, Lupin, Nesher Pharms, Upsher Smith Labs, Zydus Pharms, Alpharma Us Pharms, Fougera Pharms Inc, G And W Labs Inc, Genus, Leading, MLV, Morton Grove, Pai Holdings, Pharm Assoc, Pharmaderm, Pharmafair, Teva, Vistapharm, Wockhardt Bio Ag, Chartwell Rx, Heritage, Quantum Pharmics, Sandoz, Sun Pharm Industries, Watson Labs, Fougera, Odyssey Pharms, Alembic, Amneal, Dr Reddys, Glenmark Pharms Ltd, Lupin Ltd, Padagis Israel, Perrigo New York, Pai Holdings Pharm, and Rising. and is included in ninety NDAs.
The generic ingredient in NYSTATIN is nystatin; triamcinolone acetonide. There are eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the nystatin; triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nystatin
A generic version of NYSTATIN was approved as nystatin; triamcinolone acetonide by FOUGERA PHARMS INC on October 8th, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NYSTATIN?
- What are the global sales for NYSTATIN?
- What is Average Wholesale Price for NYSTATIN?
Summary for NYSTATIN
| US Patents: | 0 |
| Applicants: | 50 |
| NDAs: | 90 |
| Finished Product Suppliers / Packagers: | 40 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 38 |
| Patent Applications: | 3,392 |
| Drug Prices: | Drug price information for NYSTATIN |
| Drug Sales Revenues: | Drug sales revenues for NYSTATIN |
| What excipients (inactive ingredients) are in NYSTATIN? | NYSTATIN excipients list |
| DailyMed Link: | NYSTATIN at DailyMed |
Recent Clinical Trials for NYSTATIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Santiago de Compostela | N/A |
| University of Rochester | Phase 1 |
| Minia University | Early Phase 1 |
Pharmacology for NYSTATIN
| Drug Class | Polyene Antifungal |
Medical Subject Heading (MeSH) Categories for NYSTATIN
Anatomical Therapeutic Chemical (ATC) Classes for NYSTATIN
US Patents and Regulatory Information for NYSTATIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | CREAM;TOPICAL | 062364-001 | Dec 22, 1987 | AT | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva | NYSTATIN | nystatin | SUSPENSION;ORAL | 062670-001 | Jun 18, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Genus | NYSTATIN | nystatin | SUSPENSION;ORAL | 065148-001 | Jun 28, 2005 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rising | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | OINTMENT;TOPICAL | 206785-001 | Dec 29, 2016 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm Industries | NYSTATIN | nystatin | TABLET;ORAL | 062838-001 | Dec 22, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpharma Us Pharms | NYSTATIN AND TRIAMCINOLONE ACETONIDE | nystatin; triamcinolone acetonide | CREAM;TOPICAL | 063010-001 | Dec 20, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
